Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 2/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1786005 | 1.00 | AKR1C3 (0.43) | AKR1C3APEX1CA3CA6CA5A | |
| SCHEMBL1920614 | 0.84 | AKR1C3 (0.44) | AKR1C3APEX1DHODH | |
| SCHEMBL1920180 | 0.84 | AKR1C3 (0.44) | AKR1C3APEX1DHODH | |
| SCHEMBL1920181 | 0.84 | AKR1C3 (0.44) | AKR1C3APEX1DHODH | |
| SCHEMBL28791756 | 0.83 | AKR1C3 (0.43) | AKR1C3APEX1DHODHCAPN1CAPN2 | |
| SCHEMBL1431701 | 0.82 | AKR1C3 (0.46) | AKR1C3APEX1CA3CA6CA5A | |
| SCHEMBL24176985 | 0.79 | AKR1C3 (0.43) | AKR1C3APEX1CA6CA9CA14 | |
| SCHEMBL2394989 | 0.79 | AKR1C3 (0.43) | AKR1C3APEX1 | |
| SCHEMBL2394991 | 0.79 | AKR1C3 (0.43) | AKR1C3APEX1 | |
| SCHEMBL9358828 | 0.77 | TRIM24 (0.60) | APEX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124613-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124613-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | GRK5, ADRB2, GRK2 | AKR1C3 275/4885APEX1 4536/4885CA3 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.